RATIONALE: The dopamine D3 receptor has been extensively studied in animal models of drug abuse and psychosis; however, less is known on its possible role in cognitive functions. OBJECTIVES: This study investigated the effects of different D3 antagonists and a partial agonist on spatial learning performance in a water labyrinth test. METHODS: Rats had to swim through a labyrinth system by making correct directional turns at three choice-points. The number of errors was recorded in three daily trials for 3 days. RESULTS: D3 antagonists such as the highly selective SB-277011 (24 mg/kg p.o.) and RGH-1756 (1 mg/kg p.o.), the moderately selective U-99194A (12 mg/kg s.c.) and the selective partial D3 agonist BP-897 (1 mg/kg i.p.) all significantly attenuated the learning deficit caused by FG-7142. Against scopolamine-induced amnesia, SB-277011 (24 mg/kg p.o.) was equally potent in showing protective efficacy; however, two times higher dose levels of U-99194A (24 mg/kg s.c.) and RGH-1756 (2 mg/kg p.o.) were required to attenuate the scopolamine-induced impairment. In contrast to the full antagonists, against scopolamine-induced amnesia, the partial agonist BP-897 (2 mg/kg i.p.) was inactive, even at the two times higher dose level. CONCLUSIONS: These data suggest that dopamine D3 receptor antagonists possess cognition-enhancing activity which may be of benefit in the treatment of cognitive dysfunction associated with several psychiatric disorders.
RATIONALE: The dopamine D3 receptor has been extensively studied in animal models of drug abuse and psychosis; however, less is known on its possible role in cognitive functions. OBJECTIVES: This study investigated the effects of different D3 antagonists and a partial agonist on spatial learning performance in a water labyrinth test. METHODS:Rats had to swim through a labyrinth system by making correct directional turns at three choice-points. The number of errors was recorded in three daily trials for 3 days. RESULTS: D3 antagonists such as the highly selective SB-277011 (24 mg/kg p.o.) and RGH-1756 (1 mg/kg p.o.), the moderately selective U-99194A (12 mg/kg s.c.) and the selective partial D3 agonist BP-897 (1 mg/kg i.p.) all significantly attenuated the learning deficit caused by FG-7142. Against scopolamine-induced amnesia, SB-277011 (24 mg/kg p.o.) was equally potent in showing protective efficacy; however, two times higher dose levels of U-99194A (24 mg/kg s.c.) and RGH-1756 (2 mg/kg p.o.) were required to attenuate the scopolamine-induced impairment. In contrast to the full antagonists, against scopolamine-induced amnesia, the partial agonist BP-897 (2 mg/kg i.p.) was inactive, even at the two times higher dose level. CONCLUSIONS: These data suggest that dopamine D3 receptor antagonists possess cognition-enhancing activity which may be of benefit in the treatment of cognitive dysfunction associated with several psychiatric disorders.
Authors: C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan Journal: J Pharmacol Exp Ther Date: 2000-09 Impact factor: 4.030
Authors: Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner Journal: Int J Neuropsychopharmacol Date: 2006-08-31 Impact factor: 5.176
Authors: István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2008-06-12 Impact factor: 3.000
Authors: Maram A T M Khaled; Abhiram Pushparaj; Patricia Di Ciano; Jorge Diaz; Bernard Le Foll Journal: Neuropsychopharmacology Date: 2014-07-07 Impact factor: 7.853